Lumida
/CADL
⌘K
Candel Therapeutics Inc

Candel Therapeutics Inc

CADL
$10.55USD-6.93%-0.79 today

MARKET CAP

806.9M

P/E (TTM)

FWD P/E

DAY RANGE

$10 – $11

52W RANGE

$4
$14

AI Summary

Stalk
StalkMedium

CADL remains in a Stage 2 advancing uptrend with aligned moving averages, but is trading near resistance and flagged as extremely overbought. Price is tightly tracking above the 9- and 20-day EMAs, lacking a clear short-term edge. Given the Speculative strategy, patience for a pullback into the 9- to 20-day EMA zone and subsequent acceptance on rising volume is preferred.

  • BLA submission for aglatimagene besadenovec on track, with Phase III data showing 39% improvement in disease-free survival.
  • Prostate cancer market potential estimated at $10–16 billion, driving significant revenue upside if approved.
  • Q2 2026 EPS loss of $0.52 missed by $0.30; net loss widened from $4.8 M to $38.9 M YoY.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022TREND
Sales, Adj.$125,000$125,000
YoY %
P / Sales1180.7x408.1x
EV / Sales720.1x87.5x
Gross Profit, Adj.$125,000$125,000
YoY %
Margin %100.0%100.0%
EV / Gross Profit720.1x87.5x
EBITDA, Adj.$-25.5M$-33.9M
YoY %-33.1%
Margin %-20395.2%-27155.2%
EV / EBITDA-3.5x-0.3x
EBIT$-25.7M$-34.7M
YoY %-35.0%
Margin %-20580.8%-27777.6%
EV / EBIT-3.5x-0.3x
Net Income$-36.1M$-18.8M
YoY %+48.0%
Net Margin-28899.2%-15035.2%
EPS (GAAP)-$1.91-$0.65
YoY %+66.0%